Features include very common findings: Progressive visual loss, Nyctalopia, Abnormal light- and dark-adapted electroretinogram, and Yellow/white lesions of the retina and others; and common findings: Central scotoma, Photophobia, Progressive night blindness, and Retinal pigment epithelial mottling and others. 19 total HPO annotations.

No approved treatments are currently available for retinitis punctata albescens. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for retinitis punctata albescens, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for retinitis punctata albescens. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Phenotype severity distribution: 5 very common features, 7 common features.

Estimated prevalence: 1-9 in 1,000,000 (Rare).

1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.

2 publications have been identified in PubMed for retinitis punctata albescens. Research spans Case Report / Case Series (50%) and Gene Therapy / Novel Therapeutics (50%).

Recent Publications

• Baldaquí-Baeza A (2026). [PMID: 42065837](https://pubmed.ncbi.nlm.nih.gov/42065837/). *Doc Ophthalmol*. [Case Report / Case Series]

• Damodar K (2024). [PMID: 39385467](https://pubmed.ncbi.nlm.nih.gov/39385467/). *Molecular therapy : the journal of the American Society of Gene Therapy*. [Gene Therapy / Novel Therapeutics]